Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis

Nora M. Doyle, Michael O. Gardner, Lorraine Wells, Clifford Qualls, Lu Ann Papile

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Objective: Beginning in October 1995, and for several years thereafter, our institution used indomethacin as a first-line tocolytic drug. Our purpose is to compare the outcomes of very low birth weight infants who were exposed to antenatal indomethacin with those who were not exposed to this therapy. Study design: We used our center's component of the NICHD Neonatal Research Network's Generic Data Base which recorded the outcomes of all live born infants weighing less than 1500 g over a 5-year period. We abstracted data concerning neonatal morbidity (death, Grades III to IV intraventricular hemorrhage (IVH), necrotizing enterocolitis and patent ductus arteriosus), as well as other factors including gestational age, birth weight, antenatal corticosteroid treatment and maternal hypertension or pre-eclampsia. Univariate analysis was performed using Fisher's exact test. Multivariate analysis using logistic regression was performed to control for confounding factors. Results: A total of 85 infants who were exposed to antenatal indomethacin were compared to 464 infants who were not exposed to the drug. In the univariate analysis, antenatal indomethacin exposure was not associated with a significant increase in the incidence of necrotizing enterocolitis or patent ductus arteriosus. The incidence of Grades III to IV IVH was 17.9% in those infants exposed to antenatal indomethacin compared to 7.1% in the nonexposed infants (p = 0.008). The incidence of neonatal death in the exposed infants was 27.7 versus 16.4 in the nonexposed infants (p = 0.02). After controlling for antenatal corticosteroids, maternal pre-eclampsia, gestational age and birth weight, antenatal indomethacin was significantly associated with an increased incidence of IVH, but not neonatal death. Conclusion: Antenatal indomethacin was associated with significantly higher rates of IVH. Additional studies assessing the potential risk of indomethacin tocolysis are needed before it is used as a first-line tocolytic therapy.

Original languageEnglish (US)
Pages (from-to)336-340
Number of pages5
JournalJournal of Perinatology
Volume25
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis'. Together they form a unique fingerprint.

Cite this